Is Laboratorios Farmaceuticos Rovi, S.A. a good investment? Laboratorios Farmaceuticos Rovi, S.A. (ROVIN.MX) is currently trading at 1139.57 MXN.
In terms of valuation, the stock trades at a P/E ratio of 15.90. This valuation is generally in line with the broader market.
For income investors, Laboratorios Farmaceuticos Rovi, S.A. pays a dividend yield of 1.64%. With a payout ratio of 26%, the dividend appears sustainable.
Yes, it pays an annual dividend of 19.14 MXN (1.64% yield).
Laboratorios Farmaceuticos Rovi, S.A. is classified as a Stock. You can compare it against 6 other assets in the "Related Symbols" list on this page.
Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express; catheter care under the Fibrilin brand; and Sodium Heparin Rovi. In addition, the company offers contract-manufacturing services comprising compounding, sterile filling and terminal sterilisation, inspection, installation of safety devices, labelling, packaging, serialisation and aggregation, for different injectable pharmaceutical forms, such as prefilled syringes, vials and cartridges, as well as manufacturing and packaging services for solid products. Further, it offers low-molecular-weight heparin, Okedi, and Rolcya; and develops Letrozole SIE and Risperidone QUAR. Its products are used for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. The company was incorporated in 1946 and is headquartered in Pozuelo de Alarcón, Spain. Laboratorios Farmaceúticos Rovi, S.A. operates as a subsidiary of Norbel Inversiones, S.L.
| Year | Total Dividends |
|---|---|
| ▸2027 |
29.80 MXN
|
| July 5, 2027 (estimated) | 29.7980 |
| ▸2026 |
18.96 MXN
|
| July 14, 2026 | 18.9643 |
| ▸2025 |
18.48 MXN
|
| July 15, 2025 | 18.4840 |
| ▸2024 |
21.82 MXN
|
| July 9, 2024 | 21.8167 |
| ▸2023 |
25.57 MXN
|
| July 3, 2023 | 25.5743 |
| ▸2022 |
18.89 MXN
|
| July 5, 2022 | 18.8892 |
| ▸2021 |
7.54 MXN
|
| July 5, 2021 | 7.5351 |
| ▸2020 |
3.46 MXN
|
| Nov. 17, 2020 | 3.4612 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| Laboratorios Farmaceuticos Rovi, S.A. | Jul 14, 2026 | Paid | 18.964306 MXN |
Community Discussion